Furthermore, silencing PRKAR1A reduces multiple signalling pathways and can affect various intracellular signalling pathways, including MAPKs, PI3K/Akt, JAK/STAT, and Wnt/β-catenin, influencing CCA cell behaviour and growth [163]. The gene discussed is AKT1; the disease is cholangiocarcinoma.